MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT05287191
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Registry
-
NCT05287191
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Unknown status
Technical summary
Registry record NCT05287191. Randomized; single masking; primary purpose treatment. Start 2022-01-05 (actual); primary completion 2025-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care
- Acronym
- MAGNAM
- Condition
- Atrial Fibrillation New Onset
- Intervention (Drug)
- Magnesium sulfate and then Digoxin
- Intervention (Drug)
- Amiodarone
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Collaborator
- Sunnybrook Research Institute
Record details
- Record id
cardio:ct-nct05287191- Content hash
a6217ea5117405f59a9ad45944c5633d17508035e753138b097bcbe8063b2a44